孕妇及产后HIV女性中多替拉韦与依非韦伦方案的高血压随机试验分析
该随机试验纳入626名无基线高血压的孕妇,比较多替拉韦联合恩曲他滨/替诺福韦艾拉酚胺或替诺福韦二吡呋酯与依非韦伦联合方案,随访至产后50周。复合高血压事件发生率为49%,组间无显著差异,但多替拉韦组数值上更高;每增加5kg体重,复合高血压事件风险增加8%-17%。
要点
- 孕妇及产后HIV女性中复合高血压事件常见,达49%,主要为血压升高类别。
- 多替拉韦方案与依非韦伦方案相比,高血压事件无显著差异,但数值上更高。
- 体重增加与高血压风险升高相关,每增加5kg风险增加8%-17%。
核心结论
- 含多替拉韦方案与依非韦伦方案在孕妇及产后HIV女性中高血压事件无显著差异,但多替拉韦组数值上更高。
研究设计与样本
- 随机试验纳入626名无基线高血压的孕妇,随机分配至多替拉韦+F/TAF、多替拉韦+F/TDF或依非韦伦/F/TDF组,随访至产后50周。
主要发现
- 复合高血压事件发生率为49%(n=308),主要由血压升高类别构成,组间无显著差异。
- 每增加5kg体重,复合高血压事件风险增加8%-17%。
关键数值与推荐
- 复合高血压事件定义为启动降压药物或≥2次血压升高,分级为升高(130-139和/或80-89 mmHg)、轻度(140-159和/或90-99 mmHg)、中度(≥160-179和/或≥100-109 mmHg)、重度(≥180和/或≥110 mmHg)。
- 妊娠期高血压定义为≥20周妊娠时启动降压药物或≥2次血压≥140和/或≥90 mmHg,且产后12周内缓解。
临床怎么用
- 对接受多替拉韦或依非韦伦方案的孕妇及产后HIV女性,应监测体重并进行高血压筛查。
局限性
- 原文未明确列出局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We performed an analysis of incident hypertension in a randomized trial comparing dolutegravir (DTG) + emtricitabine (F)/tenofovir alafenamide (TAF) versus DTG + F/tenofovir disoproxil fumarate (TDF) versus efavirenz (EFV)/F/TDF in pregnant and postpartum women with HIV. METHODS: Women were randomized at 14-28 weeks gestational age (GA) to start DTG + F/TAF, DTG + F/TDF, or EFV/F/TDF and followed through 50 weeks postpartum. The composite incident hypertension outcome was defined as initiation of antihypertensive medication or ≥2 elevated blood pressures categorized as elevated (130-139 and/or 80-89 mmHg), mild (140-159 and/or 90-99 mmHg), moderate (≥160-179 and/or ≥100-109 mmHg), and severe (≥180 and/or ≥110 mmHg). Incident gestational hypertension was defined by initiation of antihypertensive medication or ≥2 blood pressures ≥ 140 and/or ≥90 mmHg at ≥20 weeks GA with resolution by 12 weeks postpartum. Cox proportional hazard models were used for by-arm comparisons of the composite outcome and to look for the effect of weight change within arm. RESULTS: Of 626 women without baseline hypertension (median age 26.6 years), the composite incident outcome occurred in 49% (n = 308), predominantly due to the incident elevated category of elevated blood pressure, with no significant differences by arm, although hypertension was numerically more likely in the DTG arms. Each additional 5 kg of weight was associated with an 8%-17% higher hazard of the composite hypertension outcome. Twenty-seven participants (4.3%) had gestational hypertension with no apparent differences between arms. CONCLUSIONS: Our data contribute information regarding the safety of DTG-based ART and TAF in pregnant and postpartum women and highlight the importance of monitoring weight and performing hypertension screening as part of maternal health care for young women with HIV.
引用
- Hoffman R, Brummel S, Pinilla M, et al. Hypertension in a Randomized Trial of Dolutegravir- Versus Efavirenz-Based Antiretroviral Therapy in Pregnant and Postpartum Women with HIV. Clin Infect Dis. 2026. PMID: 41973953. doi:10.1093/cid/ciag245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。